Mechanisms of age-related macular degeneration

Neuron

Volumn 75, Issue 1, 2012, Pages 26-39

  Ambati, Jayakrishna ^a,b   Fowler, Benjamin J ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; COMPLEMENT FACTOR; DICER; DICER1; IMMUNOSUPPRESSIVE AGENT; PEGAPTANIB; RANIBIZUMAB; RAPAMYCIN; REGENERON; TRIAMCINOLONE; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN ANTIBODY;

AUTOPHAGY; BLINDNESS; BLOOD VESSEL; COMPLEMENT GENE; DEGENERATIVE DISEASE; DISEASE CLASSIFICATION; ENVIRONMENTAL FACTOR; GENE; GENETIC RISK; GEOGRAPHIC ATROPHY; HUMAN; IMMUNOMODULATION; MEDICAL RESEARCH; MOLECULAR MECHANICS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RETINA; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; STEM CELL TRANSPLANTATION; SUBRETINAL NEOVASCULARIZATION;

ANIMALS; BLINDNESS; HUMANS; MACULAR DEGENERATION; PHOTORECEPTOR CELLS, VERTEBRATE; RETINA;

EID: 84863845318     PISSN: 08966273     EISSN: 10974199     Source Type: Journal    
DOI: 10.1016/j.neuron.2012.06.018     Document Type: Review

References (158)

1. Adamis A.P., Miller J.W., Bernal M.T., D'Amico D.J., Folkman J., Yeo T.K., Yeo K.T. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am. J. Ophthalmol. 1994, 118:445-450.
2. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch. Ophthalmol. 2001, 119:1417-1436. Age-Related Eye Disease Study Research Group.
3. Aiello L.P., Avery R.L., Arrigg P.G., Keyt B.A., Jampel H.D., Shah S.T., Pasquale L.R., Thieme H., Iwamoto M.A., Park J.E., et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 1994, 331:1480-1487.
4. Ambati J., Ambati B.K., Yoo S.H., Ianchulev S., Adamis A.P. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv. Ophthalmol. 2003, 48:257-293.
5. Ambati J., Anand A., Fernandez S., Sakurai E., Lynn B.C., Kuziel W.A., Rollins B.J., Ambati B.K. An animal model of age-related macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice. Nat. Med. 2003, 9:1390-1397.
6. Amin R., Puklin J.E., Frank R.N. Growth factor localization in choroidal neovascular membranes of age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 1994, 35:3178-3188.
7. Anderson D.H., Radeke M.J., Gallo N.B., Chapin E.A., Johnson P.T., Curletti C.R., Hancox L.S., Hu J., Ebright J.N., Malek G., et al. The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Prog. Retin. Eye Res. 2010, 29:95-112.
8. Batzer M.A., Deininger P.L. Alu repeats and human genomic diversity. Nat. Rev. Genet. 2002, 3:370-379.
9. Baudouin C., Peyman G.A., Fredj-Reygrobellet D., Gordon W.C., Lapalus P., Gastaud P., Bazan N.G. Immunohistological study of subretinal membranes in age-related macular degeneration. Jpn. J. Ophthalmol. 1992, 36:443-451.
10. Becerra E.M., Morescalchi F., Gandolfo F., Danzi P., Nascimbeni G., Arcidiacono B., Semeraro F. Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration. Curr. Drug Targets 2011, 12:149-172.
11. Belancio V.P., Hedges D.J., Deininger P. Mammalian non-LTR retrotransposons: for better or worse, in sickness and in health. Genome Res. 2008, 18:343-358.
12. Bhutto I.A., McLeod D.S., Hasegawa T., Kim S.Y., Merges C., Tong P., Lutty G.A. Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration. Exp. Eye Res. 2006, 82:99-110.
13. Bird A.C. Therapeutic targets in age-related macular disease. J. Clin. Invest. 2010, 120:3033-3041.
14. Blalock E.M., Buechel H.M., Popovic J., Geddes J.W., Landfield P.W. Microarray analyses of laser-captured hippocampus reveal distinct gray and white matter signatures associated with incipient Alzheimer's disease. J. Chem. Neuroanat. 2011, 42:118-126.
15. Booij J.C., ten Brink J.B., Swagemakers S.M., Verkerk A.J., Essing A.H., van der Spek P.J., Bergen A.A. A new strategy to identify and annotate human RPE-specific gene expression. PLoS ONE 2010, 5:e9341.
16. Boothby L.A., Doering P.L. Vitamin C and vitamin E for Alzheimer's disease. Ann. Pharmacother. 2005, 39:2073-2080.
17. Bora N.S., Kaliappan S., Jha P., Xu Q., Sivasankar B., Harris C.L., Morgan B.P., Bora P.S. CD59, a complement regulatory protein, controls choroidal neovascularization in a mouse model of wet-type age-related macular degeneration. J. Immunol. 2007, 178:1783-1790.
18. Bradley D.T., Zipfel P.F., Hughes A.E. Complement in age-related macular degeneration: a focus on function. Eye (Lond.) 2011, 25:683-693.
19. Brookmeyer R., Johnson E., Ziegler-Graham K., Arrighi H.M. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement. 2007, 3:186-191.
20. Brown D.M., Kaiser P.K., Michels M., Soubrane G., Heier J.S., Kim R.Y., Sy J.P., Schneider S. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 2006, 355:1432-1444. ANCHOR Study Group.
21. Cai H., Del Priore L.V. Bruch membrane aging alters the gene expression profile of human retinal pigment epithelium. Curr. Eye Res. 2006, 31:181-189.
22. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005, 438:932-936.
23. Chakravarthy U., Wong T.Y., Fletcher A., Piault E., Evans C., Zlateva G., Buggage R., Pleil A., Mitchell P. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC Ophthalmol. 2010, 10:31.
24. Charbel Issa P., Chong N.V., Scholl H.P. The significance of the complement system for the pathogenesis of age-related macular degeneration - current evidence and translation into clinical application. Graefes Arch. Clin. Exp. Ophthalmol. 2011, 249:163-174.
25. Chen Y., Zeng J., Zhao C., Wang K., Trood E., Buehler J., Weed M., Kasuga D., Bernstein P.S., Hughes G., et al. Assessing susceptibility to age-related macular degeneration with genetic markers and environmental factors. Arch. Ophthalmol. 2011, 129:344-351.
26. Cherepanoff S., McMenamin P., Gillies M.C., Kettle E., Sarks S.H. Bruch's membrane and choroidal macrophages in early and advanced age-related macular degeneration. Br. J. Ophthalmol. 2010, 94:918-925.
27. Christen W.G., Schaumberg D.A., Glynn R.J., Buring J.E. Dietary ω-3 fatty acid and fish intake and incident age-related macular degeneration in women. Arch. Ophthalmol. 2011, 129:921-929.
28. Christensen M., Schratt G.M. microRNA involvement in developmental and functional aspects of the nervous system and in neurological diseases. Neurosci. Lett. 2009, 466:55-62.
29. Ciulla T.A., Rosenfeld P.J. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration. Curr. Opin. Ophthalmol. 2009, 20:166-174.
30. Combadière C., Feumi C., Raoul W., Keller N., Rodéro M., Pézard A., Lavalette S., Houssier M., Jonet L., Picard E., et al. CX3CR1-dependent subretinal microglia cell accumulation is associated with cardinal features of age-related macular degeneration. J. Clin. Invest. 2007, 117:2920-2928.
31. Cunha-Vaz J.G. The blood-retinal barriers system. Basic concepts and clinical evaluation. Exp. Eye Res. 2004, 78:715-721.
32. Cursiefen C., Chen L., Borges L.P., Jackson D., Cao J., Radziejewski C., D'Amore P.A., Dana M.R., Wiegand S.J., Streilein J.W. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J. Clin. Invest. 2004, 113:1040-1050.
33. Doyle S.L., Campbell M., Ozaki E., Salomon R.G., Mori A., Kenna P.F., Farrar G.J., Kiang A.S., Humphries M.M., Lavelle E.C., et al. NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components. Nat. Med. 2012, 18:791-798.
34. Eacker S.M., Dawson T.M., Dawson V.L. Understanding microRNAs in neurodegeneration. Nat. Rev. Neurosci. 2009, 10:837-841.
35. Economides A.N., Carpenter L.R., Rudge J.S., Wong V., Koehler-Stec E.M., Hartnett C., Pyles E.A., Xu X., Daly T.J., Young M.R., et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat. Med. 2003, 9:47-52.
36. Edwards A.O., Ritter R., Abel K.J., Manning A., Panhuysen C., Farrer L.A. Complement factor H polymorphism and age-related macular degeneration. Science 2005, 308:421-424.
37. Ehrchen J., Steinmüller L., Barczyk K., Tenbrock K., Nacken W., Eisenacher M., Nordhues U., Sorg C., Sunderkötter C., Roth J. Glucocorticoids induce differentiation of a specifically activated, anti-inflammatory subtype of human monocytes. Blood 2007, 109:1265-1274.
38. Espinosa-Heidmann D.G., Suner I.J., Hernandez E.P., Monroy D., Csaky K.G., Cousins S.W. Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 2003, 44:3586-3592.
39. Espinosa-Heidmann D.G., Reinoso M.A., Pina Y., Csaky K.G., Caicedo A., Cousins S.W. Quantitative enumeration of vascular smooth muscle cells and endothelial cells derived from bone marrow precursors in experimental choroidal neovascularization. Exp. Eye Res. 2005, 80:369-378.
40. Evans J. Antioxidant supplements to prevent or slow down the progression of AMD: a systematic review and meta-analysis. Eye (Lond.) 2008, 22:751-760.
41. Ferrara N. Role of myeloid cells in vascular endothelial growth factor-independent tumor angiogenesis. Curr. Opin. Hematol. 2010, 17:219-224.
42. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1995, 1:27-31.
43. Ford K.M., Saint-Geniez M., Walshe T., Zahr A., D'Amore P.A. Expression and role of VEGF in the adult retinal pigment epithelium. Invest. Ophthalmol. Vis. Sci. 2011, 52:9478-9487.
44. Forooghian F., Cukras C., Meyerle C.B., Chew E.Y., Wong W.T. Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina 2009, 29:723-731.
45. Frank R.N., Amin R.H., Eliott D., Puklin J.E., Abrams G.W. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am. J. Ophthalmol. 1996, 122:393-403.
46. Friedman D.S., O'Colmain B.J., Muñoz B., Tomany S.C., McCarty C., de Jong P.T., Nemesure B., Mitchell P., Kempen J. Prevalence of age-related macular degeneration in the United States. Arch. Ophthalmol. 2004, 122:564-572. Eye Diseases Prevalence Research Group.
47. Friedman R.C., Farh K.K., Burge C.B., Bartel D.P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009, 19:92-105.
48. Fukuoka Y., Strainic M., Medof M.E. Differential cytokine expression of human retinal pigment epithelial cells in response to stimulation by C5a. Clin. Exp. Immunol. 2003, 131:248-253.
49. Glenn J.V., Mahaffy H., Dasari S., Oliver M., Chen M., Boulton M.E., Xu H., Curry W.J., Stitt A.W. Proteomic profiling of human retinal pigment epithelium exposed to an advanced glycation-modified substrate. Graefe's archive for clinical and experimental ophthalmology. Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol. 2011, 32:1407-1416.
50. Goldstein D.B. Common genetic variation and human traits. N. Engl. J. Med. 2009, 360:1696-1698.
51. Gragoudas E.S., Adamis A.P., Cunningham E.T., Feinsod M., Guyer D.R. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 2004, 351:2805-2816. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group.
52. Grossniklaus H.E., Cingle K.A., Yoon Y.D., Ketkar N., L'Hernault N., Brown S. Correlation of histologic 2-dimensional reconstruction and confocal scanning laser microscopic imaging of choroidal neovascularization in eyes with age-related maculopathy. Arch. Ophthalmol. 2000, 118:625-629.
53. Grossniklaus H.E., Ling J.X., Wallace T.M., Dithmar S., Lawson D.H., Cohen C., Elner V.M., Elner S.G., Sternberg P. Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol. Vis. 2002, 8:119-126.
54. Gu J., Pauer G.J., Yue X., Narendra U., Sturgill G.M., Bena J., Gu X., Peachey N.S., Salomon R.G., Hagstrom S.A., Crabb J.W. Assessing susceptibility to age-related macular degeneration with proteomic and genomic biomarkers. Mol. Cell. Proteomics 2009, 8:1338-1349. Clinical Genomic and Proteomic AMD Study Group.
55. Guyer D.R., Fine S.L., Maguire M.G., Hawkins B.S., Owens S.L., Murphy R.P. Subfoveal choroidal neovascular membranes in age-related macular degeneration. Visual prognosis in eyes with relatively good initial visual acuity. Arch. Ophthalmol. 1986, 104:702-705.
56. Guymer R.H., Tao L.W., Goh J.K., Liew D., Ischenko O., Robman L.D., Aung K., Cipriani T., Cain M., Richardson A.J., et al. Identification of urinary biomarkers for age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2011, 52:4639-4644.
57. Hageman G.S., Luthert P.J., Victor Chong N.H., Johnson L.V., Anderson D.H., Mullins R.F. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog. Retin. Eye Res. 2001, 20:705-732.
58. Hageman G.S., Anderson D.H., Johnson L.V., Hancox L.S., Taiber A.J., Hardisty L.I., Hageman J.L., Stockman H.A., Borchardt J.D., Gehrs K.M., et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc. Natl. Acad. Sci. USA 2005, 102:7227-7232.
59. Haines J.L., Hauser M.A., Schmidt S., Scott W.K., Olson L.M., Gallins P., Spencer K.L., Kwan S.Y., Noureddine M., Gilbert J.R., et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 2005, 308:419-421.
60. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
61. Häsler J., Strub K. Alu RNP and Alu RNA regulate translation initiation in vitro. Nucleic Acids Res. 2006, 34:2374-2385.
62. Hayat M.J., Howlader N., Reichman M.E., Edwards B.K. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 2007, 12:20-37.
63. Higgins G.T., Wang J.H., Dockery P., Cleary P.E., Redmond H.P. Induction of angiogenic cytokine expression in cultured RPE by ingestion of oxidized photoreceptor outer segments. Invest. Ophthalmol. Vis. Sci. 2003, 44:1775-1782.
64. Hollyfield J.G., Bonilha V.L., Rayborn M.E., Yang X., Shadrach K.G., Lu L., Ufret R.L., Salomon R.G., Perez V.L. Oxidative damage-induced inflammation initiates age-related macular degeneration. Nat. Med. 2008, 14:194-198.
65. Humayun M.S., Dorn J.D., da Cruz L., Dagnelie G., Sahel J.A., Stanga P.E., Cideciyan A.V., Duncan J.L., Eliott D., Filley E., et al. Interim results from the international trial of Second Sight's visual prosthesis. Ophthalmology 2012, 119:779-788. Argus II Study Group.
66. Jakobsdottir J., Gorin M.B., Conley Y.P., Ferrell R.E., Weeks D.E. Interpretation of genetic association studies: markers with replicated highly significant odds ratios may be poor classifiers. PLoS Genet. 2009, 5:e1000337.
67. Johnson L.V., Leitner W.P., Staples M.K., Anderson D.H. Complement activation and inflammatory processes in Drusen formation and age related macular degeneration. Exp. Eye Res. 2001, 73:887-896.
68. Johnson P.T., Brown M.N., Pulliam B.C., Anderson D.H., Johnson L.V. Synaptic pathology, altered gene expression, and degeneration in photoreceptors impacted by drusen. Invest. Ophthalmol. Vis. Sci. 2005, 46:4788-4795.
69. Kaneko H., Dridi S., Tarallo V., Gelfand B.D., Fowler B.J., Cho W.G., Kleinman M.E., Ponicsan S.L., Hauswirth W.W., Chiodo V.A., et al. DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration. Nature 2011, 471:325-330.
70. Karikó K., Ni H., Capodici J., Lamphier M., Weissman D. mRNA is an endogenous ligand for Toll-like receptor 3. J. Biol. Chem. 2004, 279:12542-12550.
71. Kelly J., Ali Khan A., Yin J., Ferguson T.A., Apte R.S. Senescence regulates macrophage activation and angiogenic fate at sites of tissue injury in mice. J. Clin. Invest. 2007, 117:3421-3426.
72. Klein R.J., Zeiss C., Chew E.Y., Tsai J.Y., Sackler R.S., Haynes C., Henning A.K., SanGiovanni J.P., Mane S.M., Mayne S.T., et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005, 308:385-389.
73. Klein R., Meuer S.M., Knudtson M.D., Iyengar S.K., Klein B.E. The epidemiology of retinal reticular drusen. Am. J. Ophthalmol. 2008, 145:317-326.
74. Klein M.L., Ferris F.L., Francis P.J., Lindblad A.S., Chew E.Y., Hamon S.C., Ott J. Progression of geographic atrophy and genotype in age-related macular degeneration. Ophthalmology 2010, 117:1554-1559.
75. Kleinman M.E., Yamada K., Takeda A., Chandrasekaran V., Nozaki M., Baffi J.Z., Albuquerque R.J., Yamasaki S., Itaya M., Pan Y., et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008, 452:591-597.
76. Kleinman M.E., Kaneko H., Cho W.G., Dridi S., Fowler B.J., Blandford A.D., Albuquerque R.J., Hirano Y., Terasaki H., Kondo M., et al. Short-interfering RNAs induce retinal degeneration via TLR3 and IRF3. Mol. Ther. 2012, 20:101-108.
77. Klionsky D.J. Autophagy: from phenomenology to molecular understanding in less than a decade. Nat. Rev. Mol. Cell Biol. 2007, 8:931-937.
78. Kourtis N., Tavernarakis N. Autophagy and cell death in model organisms. Cell Death Differ. 2009, 16:21-30.
79. Krishnadev N., Meleth A.D., Chew E.Y. Nutritional supplements for age-related macular degeneration. Curr. Opin. Ophthalmol. 2010, 21:184-189.
80. Kurji K.H., Cui J.Z., Lin T., Harriman D., Prasad S.S., Kojic L., Matsubara J.A. Microarray analysis identifies changes in inflammatory gene expression in response to amyloid-beta stimulation of cultured human retinal pigment epithelial cells. Invest. Ophthalmol. Vis. Sci. 2010, 51:1151-1163.
81. Kvanta A., Algvere P.V., Berglin L., Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest. Ophthalmol. Vis. Sci. 1996, 37:1929-1934.
82. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246:1306-1309.
83. Li T.H., Schmid C.W. Differential stress induction of individual Alu loci: implications for transcription and retrotransposition. Gene 2001, 276:135-141.
84. Lin M.T., Beal M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443:787-795.
85. Lopez P.F., Sippy B.D., Lambert H.M., Thach A.B., Hinton D.R. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest. Ophthalmol. Vis. Sci. 1996, 37:855-868.
86. Lu B., Malcuit C., Wang S., Girman S., Francis P., Lemieux L., Lanza R., Lund R. Long-term safety and function of RPE from human embryonic stem cells in preclinical models of macular degeneration. Stem Cells 2009, 27:2126-2135.
87. Lueck K., Wasmuth S., Williams J., Hughes T.R., Morgan B.P., Lommatzsch A., Greenwood J., Moss S.E., Pauleikhoff D. Sub-lytic C5b-9 induces functional changes in retinal pigment epithelial cells consistent with age-related macular degeneration. Eye (Lond.) 2011, 25:1074-1082.
88. Maiuri M.C., Zalckvar E., Kimchi A., Kroemer G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat. Rev. Mol. Cell Biol. 2007, 8:741-752.
89. Majumder S., Richardson A., Strong R., Oddo S. Inducing autophagy by rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits. PLoS ONE 2011, 6:e25416.
90. Manolio T.A., Collins F.S., Cox N.J., Goldstein D.B., Hindorff L.A., Hunter D.J., McCarthy M.I., Ramos E.M., Cardon L.R., Chakravarti A., et al. Finding the missing heritability of complex diseases. Nature 2009, 461:747-753.
91. Martin D.F., Maguire M.G., Ying G.S., Grunwald J.E., Fine S.L., Jaffe G.J. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 2011, 364:1897-1908. CATT Research Group.
92. Martin D.F., Maguire M.G., Fine S.L., Ying G.S., Jaffe G.J., Grunwald J.E., Toth C., Redford M., Ferris F.L. Ranibizumab and Bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012, Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group Writing Committee, Published online May 1, 2012. 10.1016/j.ophtha.2012.03.053.
93. Mattapallil M.J., Wawrousek E.F., Chan C.C., Zhao H., Roychoudhury J., Ferguson T.A., Caspi R.R. The rd8 mutation of the Crb1 gene is present in vendor lines of C57BL/6N mice and embryonic stem cells, and confounds ocular induced mutant phenotypes. Invest. Ophthalmol. Vis. Sci. 2012, 53:2921-2927.
94. McClellan J., King M.C. Genetic heterogeneity in human disease. Cell 2010, 141:210-217.
95. Mitter S.K., Rao H.V., Qi X., Cai J., Sugrue A., Dunn W.A., Grant M.B., Boulton M.E. Autophagy in the retina: a potential role in age-related macular degeneration. Adv. Exp. Med. Biol. 2012, 723:83-90.
96. Mo F.M., Proia A.D., Johnson W.H., Cyr D., Lashkari K. Interferon gamma-inducible protein-10 (IP-10) and eotaxin as biomarkers in age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2010, 51:4226-4236.
97. Molday L.L., Rabin A.R., Molday R.S. ABCR expression in foveal cone photoreceptors and its role in Stargardt macular dystrophy. Nat. Genet. 2000, 25:257-258.
98. Murakami Y., Ikeda Y., Yonemitsu Y., Miyazaki M., Inoue M., Hasegawa M., Sueishi K., Ishibashi T. Inhibition of choroidal neovascularization via brief subretinal exposure to a newly developed lentiviral vector pseudotyped with Sendai viral envelope proteins. Hum. Gene Ther. 2010, 21:199-209.
99. Newman A.M., Gallo N.B., Hancox L.S., Miller N.J., Radeke C.M., Maloney M.A., Cooper J.B., Hageman G.S., Anderson D.H., Johnson L.V., Radeke M.J. Systems-level analysis of age-related macular degeneration reveals global biomarkers and phenotype-specific functional networks. Genome Med. 2012, 4:16.
100. Nishijima K., Ng Y.S., Zhong L., Bradley J., Schubert W., Jo N., Akita J., Samuelsson S.J., Robinson G.S., Adamis A.P., Shima D.T. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am. J. Pathol. 2007, 171:53-67.
101. Noël A., Jost M., Lambert V., Lecomte J., Rakic J.M. Anti-angiogenic therapy of exudative age-related macular degeneration: current progress and emerging concepts. Trends Mol. Med. 2007, 13:345-352.
102. Nozaki M., Raisler B.J., Sakurai E., Sarma J.V., Barnum S.R., Lambris J.D., Chen Y., Zhang K., Ambati B.K., Baffi J.Z., Ambati J. Drusen complement components C3a and C5a promote choroidal neovascularization. Proc. Natl. Acad. Sci. USA 2006, 103:2328-2333.
103. Nussenblatt R.B., Byrnes G., Sen H.N., Yeh S., Faia L., Meyerle C., Wroblewski K., Li Z., Liu B., Chew E., et al. A randomized pilot study of systemic immunosuppression in the treatment of age-related macular degeneration with choroidal neovascularization. Retina 2010, 30:1579-1587.
104. O'Neill L.A., Sheedy F.J., McCoy C.E. MicroRNAs: the fine-tuners of Toll-like receptor signalling. Nat. Rev. Immunol. 2011, 11:163-175.
105. Papadopoulou D.N., Mendrinos E., Mangioris G., Donati G., Pournaras C.J. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration. Ophthalmology 2009, 116:1755-1761.
106. Patel M., Chan C.C. Immunopathological aspects of age-related macular degeneration. Semin. Immunopathol. 2008, 30:97-110.
107. Patel N., Adewoyin T., Chong N.V. Age-related macular degeneration: a perspective on genetic studies. Eye (Lond.) 2008, 22:768-776.
108. Paynter N.P., Chasman D.I., Paré G., Buring J.E., Cook N.R., Miletich J.P., Ridker P.M. Association between a literature-based genetic risk score and cardiovascular events in women. JAMA 2010, 303:631-637.
109. Penfold P.L., Liew S.C., Madigan M.C., Provis J.M. Modulation of major histocompatibility complex class II expression in retinas with age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 1997, 38:2125-2133.
110. Pons M., Marin-Castaño M.E. Cigarette smoke-related hydroquinone dysregulates MCP-1, VEGF and PEDF expression in retinal pigment epithelium in vitro and in vivo. PLoS ONE 2011, 6:e16722.
111. Raoul W., Auvynet C., Camelo S., Guillonneau X., Feumi C., Combadière C., Sennlaub F. CCL2/CCR2 and CX3CL1/CX3CR1 chemokine axes and their possible involvement in age-related macular degeneration. J. Neuroinflammation 2010, 7:87.
112. Rattner A., Nathans J. Macular degeneration: recent advances and therapeutic opportunities. Nat. Rev. Neurosci. 2006, 7:860-872.
113. Rohrer B., Long Q., Coughlin B., Wilson R.B., Huang Y., Qiao F., Tang P.H., Kunchithapautham K., Gilkeson G.S., Tomlinson S. A targeted inhibitor of the alternative complement pathway reduces angiogenesis in a mouse model of age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2009, 50:3056-3064.
114. Rosenfeld P.J., Brown D.M., Heier J.S., Boyer D.S., Kaiser P.K., Chung C.Y., Kim R.Y. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 2006, 355:1419-1431. MARINA Study Group.
115. Sacu S., Pemp B., Weigert G., Matt G., Garhofer G., Pruente C., Schmetterer L., Schmidt-Erfurth U. Response of retinal vessels and retrobulbar hemodynamics to intravitreal anti-VEGF treatment in eyes with branch retinal vein occlusion. Invest. Ophthalmol. Vis. Sci. 2011, 52:3046-3050.
116. Saint-Geniez M., Maharaj A.S., Walshe T.E., Tucker B.A., Sekiyama E., Kurihara T., Darland D.C., Young M.J., D'Amore P.A. Endogenous VEGF is required for visual function: evidence for a survival role on müller cells and photoreceptors. PLoS ONE 2008, 3:e3554.
117. Sakurai E., Anand A., Ambati B.K., van Rooijen N., Ambati J. Macrophage depletion inhibits experimental choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 2003, 44:3578-3585.
118. Scherz-Shouval R., Shvets E., Fass E., Shorer H., Gil L., Elazar Z. Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4. EMBO J. 2007, 26:1749-1760.
119. Schmitz-Valckenberg S., Fleckenstein M., Scholl H.P., Holz F.G. Fundus autofluorescence and progression of age-related macular degeneration. Surv. Ophthalmol. 2009, 54:96-117.
120. Scholl H.P., Fleckenstein M., Fritsche L.G., Schmitz-Valckenberg S., Göbel A., Adrion C., Herold C., Keilhauer C.N., Mackensen F., Mössner A., et al. CFH, C3 and ARMS2 are significant risk loci for susceptibility but not for disease progression of geographic atrophy due to AMD. PLoS ONE 2009, 4:e7418.
121. Sen C.K., Gordillo G.M., Khanna S., Roy S. Micromanaging vascular biology: tiny microRNAs play big band. J. Vasc. Res. 2009, 46:527-540.
122. Shen L., Ji H.F. Insights into the disappointing clinical trials of antioxidants in neurodegenerative diseases. J. Alzheimers Dis. 2010, 19:1141-1142.
123. Sheridan C.M., Mason S., Pattwell D.M., Kent D., Grierson I., Williams R. Replacement of the RPE monolayer. Eye (Lond.) 2009, 23:1910-1915.
124. Shiose S., Chen Y., Okano K., Roy S., Kohno H., Tang J., Pearlman E., Maeda T., Palczewski K., Maeda A. Toll-like receptor 3 is required for development of retinopathy caused by impaired all-trans-retinal clearance in mice. J. Biol. Chem. 2011, 286:15543-15555.
125. Sica A., Larghi P., Mancino A., Rubino L., Porta C., Totaro M.G., Rimoldi M., Biswas S.K., Allavena P., Mantovani A. Macrophage polarization in tumour progression. Semin. Cancer Biol. 2008, 18:349-355.
126. Skeie J.M., Mullins R.F. Macrophages in neovascular age-related macular degeneration: friends or foes?. Eye (Lond.) 2009, 23:747-755.
127. Spaide R.F. Rationale for combination therapies for choroidal neovascularization. Am. J. Ophthalmol. 2006, 141:149-156.
128. Stahl A., Paschek L., Martin G., Gross N.J., Feltgen N., Hansen L.L., Agostini H.T. Rapamycin reduces VEGF expression in retinal pigment epithelium (RPE) and inhibits RPE-induced sprouting angiogenesis in vitro. FEBS Lett. 2008, 582:3097-3102.
129. Streilein J.W. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat. Rev. Immunol. 2003, 3:879-889.
130. Strunnikova N.V., Maminishkis A., Barb J.J., Wang F., Zhi C., Sergeev Y., Chen W., Edwards A.O., Stambolian D., Abecasis G., et al. Transcriptome analysis and molecular signature of human retinal pigment epithelium. Hum. Mol. Genet. 2010, 19:2468-2486.
131. Sun H., Nathans J. Stargardt's ABCR is localized to the disc membrane of retinal rod outer segments. Nat. Genet. 1997, 17:15-16.
132. Szumiel I. Autophagy, reactive oxygen species and the fate of mammalian cells. Free Radic. Res. 2011, 45:253-265.
133. Takeda A., Baffi J.Z., Kleinman M.E., Cho W.G., Nozaki M., Yamada K., Kaneko H., Albuquerque R.J., Dridi S., Saito K., et al. CCR3 is a target for age-related macular degeneration diagnosis and therapy. Nature 2009, 460:225-230.
134. Tarallo V., Hirano Y., Gelfand B.D., Dridi S., Kerur N., Kim Y., Cho W.G., Kaneko H., Fowler B.J., Bogdanovich S., et al. DICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88. Cell 2012, 149:847-859.
135. Tatar O., Yoeruek E., Szurman P., Bartz-Schmidt K.U., Adam A., Shinoda K., Eckardt C., Boeyden V., Claes C., Pertile G., et al. Effect of bevacizumab on inflammation and proliferation in human choroidal neovascularization. Arch. Ophthalmol. 2008, 126:782-790. Tübingen Bevacizumab Study Group.
136. Thornton J., Edwards R., Mitchell P., Harrison R.A., Buchan I., Kelly S.P. Smoking and age-related macular degeneration: a review of association. Eye (Lond.) 2005, 19:935-944.
137. Thurman J.M., Renner B., Kunchithapautham K., Ferreira V.P., Pangburn M.K., Ablonczy Z., Tomlinson S., Holers V.M., Rohrer B. Oxidative stress renders retinal pigment epithelial cells susceptible to complement-mediated injury. J. Biol. Chem. 2009, 284:16939-16947.
138. Tong J.P., Lam D.S., Chan W.M., Choy K.W., Chan K.P., Pang C.P. Effects of triamcinolone on the expression of VEGF and PEDF in human retinal pigment epithelial and human umbilical vein endothelial cells. Mol. Vis. 2006, 12:1490-1495.
139. Tuo J., Bojanowski C.M., Zhou M., Shen D., Ross R.J., Rosenberg K.I., Cameron D.J., Yin C., Kowalak J.A., Zhuang Z., et al. Murine ccl2/cx3cr1 deficiency results in retinal lesions mimicking human age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2007, 48:3827-3836.
140. Underwood B.R., Imarisio S., Fleming A., Rose C., Krishna G., Heard P., Quick M., Korolchuk V.I., Renna M., Sarkar S., et al. Antioxidants can inhibit basal autophagy and enhance neurodegeneration in models of polyglutamine disease. Hum. Mol. Genet. 2010, 19:3413-3429.
141. Walshe T.E., Dole V.S., Maharaj A.S., Patten I.S., Wagner D.D., D'Amore P.A. Inhibition of VEGF or TGF-beta signaling activates endothelium and increases leukocyte rolling. Arterioscler. Thromb. Vasc. Biol. 2009, 29:1185-1192.
142. Wang H., Wittchen E.S., Jiang Y., Ambati B., Grossniklaus H.E., Hartnett M.E. Upregulation of CCR3 by age-related stresses promotes choroidal endothelial cell migration via VEGF-dependent and -independent signaling. Invest. Ophthalmol. Vis. Sci. 2011, 52:8271-8277.
143. Wang Y., Wang V.M., Chan C.C. The role of anti-inflammatory agents in age-related macular degeneration (AMD) treatment. Eye (Lond.) 2011, 25:127-139.
144. Warburg O. Uber die klassifizierung tierischer gewebe nach ihrem stoffwechsel. Biochem. Z. 1928, 184:484-488.
145. Wiesen J.L., Tomasi T.B. Dicer is regulated by cellular stresses and interferons. Mol. Immunol. 2009, 46:1222-1228.
146. Willett C.G., Boucher Y., Duda D.G., di Tomaso E., Munn L.L., Tong R.T., Kozin S.V., Petit L., Jain R.K., Chung D.C., et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J. Clin. Oncol. 2005, 23:8136-8139.
147. Winkler B.S., Boulton M.E., Gottsch J.D., Sternberg P. Oxidative damage and age-related macular degeneration. Mol. Vis. 1999, 5:32.
148. Wong E., Cuervo A.M. Autophagy gone awry in neurodegenerative diseases. Nat. Neurosci. 2010, 13:805-811.
149. Wong T.Y., Chakravarthy U., Klein R., Mitchell P., Zlateva G., Buggage R., Fahrbach K., Probst C., Sledge I. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology 2008, 115:116-126.
150. Woolcock K.J., Gaidatzis D., Punga T., Bühler M. Dicer associates with chromatin to repress genome activity in Schizosaccharomyces pombe. Nat. Struct. Mol. Biol. 2011, 18:94-99.
151. Yakovchuk P., Goodrich J.A., Kugel J.F. B2 RNA and Alu RNA repress transcription by disrupting contacts between RNA polymerase II and promoter DNA within assembled complexes. Proc. Natl. Acad. Sci. USA 2009, 106:5569-5574.
152. Yang Z., Stratton C., Francis P.J., Kleinman M.E., Tan P.L., Gibbs D., Tong Z., Chen H., Constantine R., Yang X., et al. Toll-like receptor 3 and geographic atrophy in age-related macular degeneration. N. Engl. J. Med. 2008, 359:1456-1463.
153. Zarbin M.A. Current concepts in the pathogenesis of age-related macular degeneration. Arch. Ophthalmol. 2004, 122:598-614.
154. Zarbin M.A. Retinal pigment epithelium-retina transplantation for retinal degenerative disease. Am. J. Ophthalmol. 2008, 146:151-153.
155. Zhou J., Pham L., Zhang N., He S., Gamulescu M.A., Spee C., Ryan S.J., Hinton D.R. Neutrophils promote experimental choroidal neovascularization. Mol. Vis. 2005, 11:414-424.
156. Zhou J., Jang Y.P., Kim S.R., Sparrow J.R. Complement activation by photooxidation products of A2E, a lipofuscin constituent of the retinal pigment epithelium. Proc. Natl. Acad. Sci. USA 2006, 103:16182-16187.
157. Zhou R., Yazdi A.S., Menu P., Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature 2011, 469:221-225.
158. Zweifel S.A., Imamura Y., Spaide T.C., Fujiwara T., Spaide R.F. Prevalence and significance of subretinal drusenoid deposits (reticular pseudodrusen) in age-related macular degeneration. Ophthalmology 2010, 117:1775-1781.